Cilique® – Bioequivalent to Cilest®

Cilique contraceptive packet

  • Contains 35 mcg ethinylestradiol and 250 mcg norgestimate, exactly the same active ingredients as Cilest® 1,2
  • Indicated for the prevention of pregnancy in women who elect to use oral contraception 1,2
  • Causes changes in the endometrium and cervical mucus 1,2
  • Reliable, highly effective and well tolerated oral contraceptive when taken correctly 1
  • Side effects may include depressed mood and depression.1

CILIQUE ®  is suitable for use in the following patient groups: 3,4

  • Women who want autonomy and control over their menstrual cycle
  • Women aged up to 50 years with no other medical conditions
  • Women ≥6 months postpartum if fully breastfeeding
  • Women ≥6 weeks postpartum if not breastfeeding
  • Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
  • Women with endometriosis


  1. Cilique® SPC
  2. Cilest® SPC available at
  3. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.
  4. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update

IE/OCS/0119/0101(1) Date of Preparation: March 2019

Web design by

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.